BNB Chain's ERC-8004 identity registry recorded 392,228 agent IDs as of October 26, an increase of 15,688 from the previous week. This count includes all registered identities, including test, duplicate, and abandoned IDs, and does not indicate how many agents are actively in use or funded. The registry tracks identity registrations but not payments or completed tasks, reflecting the size of the identity base rather than real application demand. BNB Chain previously noted that while the identity base is large, the actual volume of paid work by agents remains to be proven.
BNB Chain's ERC-8004 identity registry is noted here with data as of Nov 02, 2026 17:31 WIB. For readers following the broader cryptocurrency market, Pluang's snapshot shows that out of 50 major cryptocurrencies, 6 rose and 42 fell today. Notable movers include THETA at Rp2.790 with a 1-day change of -3.89%, CRV at Rp4.992 down 3.52%, and ONE at Rp20 down 3.36%.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
